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CONCLUSION:
Measurement of innate immune response biomarkers in peritoneal 
dialysis effluent using a rapid diagnostic point-of-care device as a 
diagnostic indicator of peritonitis.




Peritonitis is a significant complication of
PD. A point of care test which reliably
diagnoses or excludes peritonitis would
improve patient care.
The PERiPLEX® device uses a lateral flow
assay to detect MMP-8 and IL-6 in
dialysate within minutes. We investigated
the test characteristics of this device in
107 PD patients presenting with a










The PERiPLEX® test could have significant
clinical utility for diagnosis of peritonitis.
The PERiPLEX® test
• had a high negative predictive value
(98%).
• performed better than usual clinical
signs, excluding peritonitis in 27 of
74 patients presenting with
abdominal pain or a cloudy bag.
• required  “number needed to test” 
of 6 to improve patient management 
compared to clinical assessment.
• had 8 false positives requiring
additional testing
[QUERY TO AUTHOR: title and abstract rewritten by Edito rial Office – not subject to change] 
Measurement of innate immune response biomarkers in peritoneal 
dialysis effluent using a rapid diagnostic point-of-care device as a 
diagnostic indicator of peritonitis. 
 
Catriona Goodlad, MD, Royal Free Hospital, London, UK 
Sophiamma George, Royal Free Hospital, London, UK 
Shella Sandoval, Royal Free Hospital, London, UK 
Stephen Mepham, Royal Free Hospital, London, UK 
Gita Parekh, PhD, Mologic Inc, Thurleigh, Bedfordshire, UK 
Matthias Eberl, PhD, Division of Infection and Immunity, School of Medicine and Systems 
Immunity Research Institute, Cardiff University, Cardiff, UK. 
Nicholas Topley, PhD, Wales Kidney Research Unit, Cardiff University School of Medicine, 
Cardiff, UK. 
Andrew Davenport, MD, Royal Free Hospital, London, UK and Centre for Nephrology, 
University College London, London, UK 
 
Corresponding address: 
Dr Cate Goodlad 




Running headline: “A rapid POC diagnostic test for pe itonitis” 
 











Peritonitis is the commonest complication of peritoneal dialysis and a major reason for 
treatment failure. Current diagnosis is based on clinical symptoms, cloudy effluent and a 
dialysate white cell count (over 100 cells/µl). A rapid point-of-care diagnostic test would 
accelerate diagnosis and potentially improve outcomes from infection. Here, in a clinical 
audit project, we used PERiPLEX®, a point-of-care device which detects when  levels of 
matrix metalloproteinase-8 and interleukin-6 are elevated above a threshold within minutes in 
dialysis effluent, to assess whether it could confirm or exclude peritonitis in 107 patients 
undergoing peritoneal dialysis. Mean patient age was 64.6 years with a median duration of 
peritoneal dialysis of 3.5 months (interquartile range 6.4 – 31.5 months). Presence of 
peritonitis was confirmed by clinical criteria. There were 49 positive tests of which 41 
patients had peritonitis, three had other causes of intra-peritoneal inflammation, three had 
severe urosepsis and two patients required no treatment. Fifty eight tests were negative with 
one patient having a false negative result. The positive predictive value of the test was 83.7% 
(95% confidence interval 72.8 – 90.8) and the negative predictive value was 98.3% (89.1 – 
99.8). Sensitivity and specificity were 97.6% (87.4 – 99.9) and 87.7% (77.2 – 94.5) 
respectively. Thus, PERiPLEX® could be used as a rapid point-of-care test that can aid the 














Peritonitis remains the major cause of peritoneal dialysis (PD) technique failure and transfer 
to haemodialysis1 or adverse outcomes2. When PD peritonitis is suspected, making the correct 
diagnosis quickly is important to permit rapid initiation of appropriate antibiotic treatment 
and improve outcomes3. Some patients present with clinically obvious features such as 
cloudy effluent dialysate and abdominal pain4 but the diagnosis of infection is not always 
immediately clear. Some patients present with a cloudy bag and minimal symptoms, and 
there are causes other than infection for hazy fluid. Patients using automated PD (APD) may 
have their dialysis effluent drained directly, so be unaware of its appearance. Often, a 
standard two or four-hour dwell of PD dialysate is required5. The drained dialysate is sent for 
formal cell count to confirm or exclude peritonitis4. Excluding peritonitis rapidly in patients 
with a cloudy bag who are clinically well would allow these patients to be reassured and 
discharged home. Other PD patients present feeling generally unwell and their dialysis 
effluent is analysed as part of a wider diagnostic creen. A secure diagnosis of peritonitis in 
this group would allow the earlier initiation of intra-peritoneal antibiotics, while rapid 
exclusion of peritonitis would focus management on obtaining an alternative diagnosis. 
 
The PERiPLEX® device was developed by Mologic Inc. (Thurleigh, Bedfordshire, UK) as 
part of a National Institute for Health Research (NIHR) Invention for Innovation (i4i) grant, 
in collaboration with Cardiff University. It uses the unique specificity of the immune 
response to detect infection6. PERiPLEX® is a CE marked, single use, point of care (POC) 
device designed to be used by health professionals or patients. PERiPLEX® detects matrix 
metalloproteinase-8 (MMP-8) and interleukin 6 (IL-6) using lateral flow technology. MMP-8 
is produced by activated neutrophils during acute inflammation and facilitates recruitment 
and trafficking of inflammatory cells7. MMP-8 detection during acute inflammation has been 
explored in peri-implant infections8, periodontal inflammation9 and intra-peritoneal bacterial 
infection10. IL-6 is present in the effluent dialysate of PD patients11 and is a key regulator of 
acute peritoneal inflammation in response to infection12. Although IL-6 is detectable in the 
effluent dialysate of healthy PD patients, concentrations are significantly elevated early 
during an episode of peritonitis13.  
 
This clinical audit project assessed PERiPLEX® as a means of rapidly detecting/excluding 
infection in a “real-world” clinical environment using 107 dialysis effluent samples collected 
in satellite unit PD clinics, the emergency department and the inpatient wards. 
 
Results 
A single fresh dialysis effluent sample was collected from 107 different PD patients between 
November 2017 and October 2019. Patients presented dir ctly to the PD nurses or were 
referred with suspected PD peritonitis, or to exclude PD peritonitis. Mean patient age was 
64.6 (SD 15.3) years, median duration of PD was 13.3 (inter-quartile range 6.3 – 33.5) 
months. 53% of patients were male and 34% diabetic. All patients used standard lactate-
containing dextrose dialysis solutions (Baxter Healthcare, Deerfield, USA). Icodextrin (7.5%) 
(Baxter Healthcare, Deerfield, USA) was used in 75% of the patients. Table 1 reports the 
clinical characteristics of the patients tested. 
 
Table 1: Clinical characteristics of patients at presentation  
 n % 
Abdominal pain: 
Severe abdominal pain 6 6 
Moderate abdominal pain 26 24 
Mild abdominal pain 29 27 
No abdominal pain 46 43 
Clinical suspicion of peritonitis:  
High 31 29 
Moderate 24 22 
Low 52 49 
Main indication for testing: 
Cloudy dialysate bag 40 37 
Septic screen 32 30 
Abdominal pain 20 19 
Line contamination / exit site infection 6 6 
Other / indication not recorded 9 8 
Sample obtained from a dwell of 4 hours 92 86 
 
The results are summarised in Figure 1. 
 
Microbiology results from 42 patients treated for pe itonitis are shown in Table 2: 
 
Table 2: Microbiology culture results from patients treated for peritonitis 
Organism Number of cases 
Staphylococcus epidermidis 6 
Other coagulase negative staphylococci 7 
Staphylococcus aureus 2 
Klebsiella species 2 
Pseudomonas species 4 
Enterococcus species 1 
Enterobacter species 1 
Escherichia coli 1 
Stenotrophomonas maltophilia 1 
Ochrobactrum anthropi 1 
Actinomyces naeslundii 1 
Corynebacterium species 3 
Streptococcus oralis 1 
Gordonia species 1 
Culture negative 10 
 
Although 46 patients met the International Society of Peritoneal Dialysis (ISPD) definition of 
PD peritonitis on laboratory grounds (dialysate white cell count (WCC) >100 cells/µL), 5 
patients did not clinically have peritonitis, were not prescribed antibiotics and did not 
subsequently develop peritonitis or have positive microbiology cultures. In 3 of these 5 
patients the PERiPLEX® was correctly negative: one patient had not performed PD for some 
days (WCC 405 cells/µL), one had a chyle leak (WCC 470 cells/µL) and the third had a 
WCC of 210 cells/µL without clinical peritonitis. In 2 of these 5 patients the PERiPLEX® 
was falsely positive; one had an infected lymphocele and the other urosepsis.  
One further patient with a WCC of 54 cells/µL had a clinical diagnosis of peritonitis (and was 
PERiPLEX® positive). 
 
The relationship between effluent WCC (cells/µL) and PERiPLEX® results is shown in 
Figure 2 and Figure 3 examines the relationship betwe n the microbiology culture and 
PERiPLEX® results. As expected, some patients with clinical PD peritonitis were culture 
negative (the ISPD standard is < 20% of cases)4. Both PD WCC and PERiPLEX® 
misclassified some cases; a PD WCC of >100 cells/µL had a lower rate of false positive 
results, although the PERiPLEX® has the significant advantage of providing information 
more rapidly. 
 
Table 3 summarises patients in whom the PERiPLEX® result was non-concordant with the 
ultimate clinical diagnosis:  
 
Table 3: Characteristics of the patients with non-ccordant PERiPLEX® results 
False positive results: 
Clinical Diagnosis Dialysate 
WCC 
(cells/µL) 





Systemic sepsis with 















local generation of 
mediators of 
inflammation 




Infected lymphocele (on 
CT and at later surgery) 
690 
N/A 








cultured but no clinical 







False negative results: 
Clinical Diagnosis Dialysate 
WCC 
(cells/µL) 
Cytology Possible explanation 
Previously treated episode 






cultures and 16S 
rDNA PCR negative 
 
Leukocytes present 
after treatment did not 
produce the mediators 
required to generate a 
positive result 
 
Compared to the combination of abdominal pain or cloudy bag (presenting symptoms 
specified in ISPD guidelines as suggestive of peritonitis4), PERiPLEX® has substantially 
better test performance (Table 4). Of 28 patients wi h abdominal pain or a cloudy bag who 
were PERiPLEX® negative, only one had PD peritonitis as the final di gnosis (Figure 4). 
 
Clinical judgement also determines initial management of patients with suspected peritonitis. 
Importantly, PERiPLEX® was positive and correctly diagnosed peritonitis in 5 of 50 (10%) 
patients where the clinicians had thought peritonitis unlikely, and excluded peritonitis in 13 
of 57 (22.8%) patients where clinical suspicion had been moderate or high. The use of 
PERiPLEX® might therefore have changed management in at least 18 of the 107 
presentations (16.8%), giving a “number needed to test” of six. 
 
The PERiPLEX® had high negative and positive predictive values (Table 4). The likelihood 
ratios indicate that a positive test has a strong probability of indicating PD peritonitis. 
Equally, a negative test has a very high probability of excluding PD peritonitis, resulting in a 
very strongly positive diagnostic odds ratio of 292.  
 
 Table 4: Summary of test characteristics 
  PERiPLEX % 
(95% confidence 
intervals) 
Abdominal pain or 
cloudy bag % (95% 
confidence 
intervals)  
PD WCC > 100 










83.7 (72.8 – 90.8) 55.1 (49.3 – 61.3) 91.3 (80.2 – 96.5) 97 (82 – 99.6) 
Negative predictive 
value 
98.3 (89.1 – 99.8) 97 (82 – 100) 93.8 (84.7 – 98.3) 86.3 (78.6 – 91.6) 
Sensitivity 
 
97.6 (87.4 – 99.9) 97.6 (97.4 – 99.9) 97.6 (87.7 – 99.9) 76.2 (60.6 – 88) 
Specificity 
 
87.7 (77.2 – 94.5) 49.2 (36.6 – 61.9) 93.8 (84.7 – 98.3) 98.4 (91.6 – 100) 
Positive likelihood 
ratio 
7.93 (4.14 – 15.2) 1.92 (1.51 – 2.45) 15.63 (6.04 – 40.4) 48.8 (6.92 – 343.4) 
Negative 
likelihood ratio 
0.03 (0 – 0.19) 0.05 (0.01 – 0.34) 0.02 (0 – 0.17) 0.24 (0.14 – 0.42) 
Accuracy 
 
91.6 (84.6 – 96.1) 68.2 (58.5 – 76.9) 95.3 (89.4 – 98.5) 89.6 (82.2 – 94.7) 
 
Discussion 
Peritonitis is the most important complication of PD therapy and accounts for the majority of 
technique failures1,2. Traditionally, the diagnosis of infection is based on clinical symptoms, a 
raised PD effluent leukocyte count (cloudy bag) and eventually microbiological culture 
results. To increase the yield from microbiological u tures ISPD guidelines recommend a 
minimum 2 hour dwell of fresh dialysate4. Many PD patients use APD cyclers with shorter 
dwell times, and the need for an additional dwell days diagnosis and management. A simple 
POC test that can quickly support or refute the diagnosis of PD peritonitis and avoid delay in 
initiating antibiotic treatment could improve patient outcomes3. 
 
Tests used to diagnose serious conditions like peritonitis must have favourable test 
characteristics. We found a sensitivity of 97.6% and specificity of 87.7%, with a diagnostic 
accuracy of 92%. PERiPLEX® had high positive and negative predictive values. These tests 
may be adjusted to a prevalence of 50%14; in our study 46% of tests were positive with a 
peritonitis prevalence of 39%. The level of clinical suspicion (pre-test probability) was 
evenly distributed and represents a “real-life” sample of patients. In clinical practice PD 
effluent is often tested to exclude peritonitis when the cause of inflammation is suspected to 
lie elsewhere; similarly, some patients with hazy fluid alone appear at low risk of peritonitis, 
but clinicians do not wish to miss this diagnosis. Given the high negative predictive value of 
98.3% and negative likelihood ratio of 0.0315, if the test is negative clinically well patients 
can be reassured and discharged. In a symptomatic PD patient, a negative PERiPLEX® result 
should prompt investigation for an alternative diagnosis. 
 
False positive results 
There were 8 positive tests in patients without PD peritonitis. A false positive PERiPLEX® 
result arises from an alternative cause of inflammatory mediators in the dialysate. MMP-8 is 
a mediator of the response to intra-abdominal sepsi10. Plasma IL-6 rises with systemic 
inflammation and IL-6 transfers across the peritoneal membrane into the dialysate16,17. 
Patients with false positive PERiPLEX® results and systemic sepsis are likely to have transfer 
of inflammatory mediators from the circulation and those with intra-abdominal inflammation 
may have locally generated mediators. Additional markers in future POC devices might 
increase specificity and positive predictive value by detecting the consequences of more 
complex systemic activation. 
A false positive PERiPLEX® result could lead to the inappropriate institution of antibiotics; 
however, in 5 of the 8 patients with false positive results antibiotic therapy was warranted to 
treat other infectious conditions. Further testing can be undertaken and antibiotic treatment 
refined or stopped as clinically appropriate.  
 
False negative results 
The only false negative case followed recent treatmn  of PD peritonitis. The elevated PD 
WCC (310 cells/µL) was predominantly a lymphocytosis. The PERiPLEX® is designed to 
detect the products of activated neutrophils and a lymphocytic infiltrate may not generate the 
necessary biomarker profile (particularly MMP-8). 
 
Could the PERiPLEX® change clinical management? 
Seventy four patients presented with abdominal pain and/or a cloudy bag. Of these, 
PERiPLEX® was appropriately negative in 27 patients, with one false negative result. 
Management in these 27 patients could have concentrat d on finding alternative diagnoses. 
While experienced clinicians synthesise more factors than the presence / absence of 
abdominal pain or cloudy fluid when deciding initial management, using PERiPLEX® could 
still improve patient care. Eight patients with low initial clinical suspicion for PD peritonitis 
had a positive PERiPLEX®; 5 were subsequently treated for peritonitis. PERiPLEX® could 
modify the index of clinical suspicion resulting in earlier antibiotic initiation.  
Where clinical suspicion was moderate or high, 13 patients had a negative PERiPLEX® 
result, none of whom subsequently had evidence of peritonitis. These patients could have 
been discharged home more quickly, on the basis of the PERiPLEX® result alone. Intra-
peritoneal antibiotics would be avoided and good antibiotic stewardship facilitated. 
Three patients with a negative PERiPLEX® and negative fluid cultures had a dialysate WCC 
> 100 cells/µL. None of these patients required treatm nt for peritonitis. A negative 
PERiPLEX® would provide evidence that antibiotics are not immediately required, pending 
results of microbiological cultures. 
Recent survey data indicates that peritonitis remains the major concern and feared 
complication for patients using PD therapy18. A test which permits rapid reassurance that 
peritonitis is very unlikely has the potential to reduce this significant patient anxiety. 
 
Areas for further investigation 
IL-6 concentrations in dialysate remain high for weeks after PD peritonitis19, and recurrent 
episodes of peritonitis disrupt normal peritoneal cytokine patterns over a prolonged period20. 
Further studies are required to determine whether t IL-6 component of PERiPLEX® is a 
reliable marker for detecting recurrent peritonitis.  
Studies suggest that peritoneal IL-6 does not differ between those using dual chamber PD 
dialysates compared to conventional dialysates21, although IL-6 may be greater in those 
prescribed Icodextrin22. However, as 75% (80) of our samples were taken from patients who 
used Icodextrin it does not appear that this adversely affects the utility of PERiPLEX® 
testing. The number of positive tests in Icodextrin users was 39 (including 4 false positives) 
with 41 negative tests and results in this group reflect those in the cohort as a whole. 
There are a number of IL-6 phenotypes23. We did not characterise our patients as high or low 
IL-6 producers, and are unable to comment on whether IL-6 phenotypes may affect test 
performance23. MMP-8 should in theory only be produced in early inflammation by activated 
PMN and might be a superior indicator of the presence or absence of recurrent infection6,24,25, 
but further work is needed to explore results of testing with PERiPLEX® in this clinical 
situation.  
The number of markers used in a test designed to provide a “yes/no” answer is limited by the 
need for a simple, cost-effective device. Additional markers might provide a clinically 
relevant improvement in test characteristics, or might categorise the peritoneal inflammatory 
response as due to, for example, a Gram negative organism,26 but at the expense of increased 
cost. 
Follow up studies should include regular PERiPLEX® testing to examine its day-to-day 
utility in detecting infection, its relationship to symptoms and its usefulness in predicting 
recovery, response to antibiotic therapy or relapse. 
 
Summary 
In 107 samples from PD patients who had suspected PD peritonitis, or in whom the diagnosis 
of PD peritonitis needed to be excluded, the PERiPLEX® had a positive predictive value of 
84% and a negative predictive value of 98% for PD peritonitis, diagnosed clinically on the 
basis of PD WCC >100 cells/µL, presenting symptoms, microbiology results and evolution of 
the clinical episode. PERiPLEX® testing provides immediate information at initial 
assessment and correctly excluded peritonitis in 27 of 4 patients presenting with either 
abdominal pain or a cloudy bag. When assessed against the initial level of clinical suspicion 
for peritonitis, the test might have improved the management of 18 of 107 patients, with a 
number needed to test of six. Responding to the PERi LEX® result rather than waiting for 
confirmatory results from a four-hour dwell would have expedited care. We therefore suggest 
the PERiPLEX® may have significant clinical utility, with the caveat that as with any test the 
results must be interpreted in the context of the clinical presentation and appropriate follow 
up instituted.  
 
Methods 
Study participants and eligibility:  
All PD patients with a cloudy PD effluent dialysate or abdominal symptoms, or in whom the 
attending clinicians suspected peritonitis or wished to exclude peritonitis, were tested. There 
were no exclusion criteria, but as PD nurses performed all PERiPLEX® tests, patients 
presenting out of hours were not included and the tested group is a convenience sample. 
Patients could present to our main hospital or any of our satellite PD clinics. We did not 
specify duration of sample dwell, in order to include shorter – dwell samples from patients 
using APD (as biomarker levels might be expected to be lower in this group27). In total 107 
tests were performed on 107 patients. Dialysate was tested as soon as it was drained – before 
cell counts or culture results were available. 
 
Data collection: 
Data were collected between November 2017 and October 2019. We recorded the clinical 
indication for testing, the presence or absence of abdominal pain, pyrexia and cloudy 
dialysate. The PD nurses documented their pre-test clinical suspicion of PD peritonitis. Data 
were recorded on the dialysate WCC and the final microb ological culture results.  
 
PERiPLEX®: 
The PERiPLEX® device detects MMP-8 and IL-6 using lateral flow technology; for guidance 
on use see https://mologic.co.uk/our-core-markets/infection-and-infectious-disease/periplex. 
The wick is dipped into a sample of dialysate. After ive minutes, a control line in the ‘read’ 
window indicates the test has worked correctly. If either result line is visible the test is 
positive (Figure 5). The test reader was the PD nurse and was aware of patient’s clinical 
condition; the test was read prior to availability of dialysate WCC and culture results. 
The PERiPLEX® device was developed through a NIHR i4i collaborati n between Mologic 
Inc. and Cardiff University, registered on the UK Clinical Research Network Study Portfolio 
(reference number #11838 "Patient immune responses to infection in PD (PERIT-PD)") and 
approved by the South East Wales Local Ethics Committee (04WSE04/27). Briefly, samples 
from 66 peritonitis patients and 55 stable patients were obtained from the Cardiff PD patient 
cohort and via the Tropical Pathology and Infectious Disease Association (study ethics 
approved by the TPaIDA-IPTEI Institutional Ethics Committee). IL-6 levels in cell-free 
peritoneal effluent were analyzed on a SECTOR Imager 6000 (Meso Scale Discovery) and 
with a conventional ELISA kit (Catalogue Number DY206, R&D Systems). MMP-8 was 
measured using a conventional ELISA kit (Catalogue N mber DY908, R&D Systems). The 
samples were then tested with the PERiPLEX® lateral flow assay and the output quantified 
using the Cube-Reader (opTricon, Germany); levels wre in concordance with those obtained 
using the reference assays. Biomarker levels in patients with and without peritonitis differed 
significantly (p < 0.0001, Mann-Whitney test). Visible result lines in the PERiPLEX® are 
generated only when levels of MMP-8 and IL-6 are above those in the stable population, with 
cut-off points of 0.126 ng/mL for IL-6 and 1.183 ng/mL for MMP-8. The area under the ROC 
curve was 0.966 (0.928 – 1.000) for IL-6 and 0.988 (0.974 – 1.000) for MMP-8 (determined 
using GraphPad Prism 6). Figure 6 shows the distribution of IL-6 and MMP-8 levels with the 
PERiPLEX® threshold values marked. 
 
Further Diagnostics: 
Dialysate was sent for Gram stain, WCC and microbiol g cal culture using both blood agar 
plates and BD BACTEC™ (Becton Dickinson Diagnostic Instrument Systems, Sparks, 
USA). Dialysate was also sent with EDTA to maximise th  percentage of samples suitable 
for cell count. The majority of samples were also sent for cytology cytospin analysis. 
Recognising that none of these tests alone are sufficient to make or refute a diagnosis of PD 
peritonitis, the reference standard therefore was whether the clinical team determined the 




This was a clinical service evaluation. PERiPLEX® testing was introduced into routine 
practice, with PERiPLEX® devices placed with peritonitis packs on the wards and in each 
satellite unit PD clinic. Clinicians were instructed not to alter clinical management based on 
PERiPLEX® result. Our service development audit complied with the United Kingdom (UK) 
National Health Service Health Research Authority guidelines for clinical audit and service 
development (https://www.hra.nhs.uk), and was regist red with the UCL Department of 
Nephrology, Royal Free Hospital. All patient data were anonymised. The audit complied with 




This clinical audit project was the first use of the PERiPLEX® in the clinical environment. 
The data therefore represent a convenience sample with no prior calculation of sample size.  
Data to be collected were determined prior to initiating the study. There were no missing 
PERiPLEX® results. All but one patient had results of microbiology cultures and all had a PD 
WCC result. We calculated the test sensitivity, specificity, positive and negative predictive 
values and the test likelihood ratios. 
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Figure 1: STARD diagram of patient results 
 
Figure 2: PERiPLEX® results and PD WCC 
 
Figure 3: PERiPLEX® results and microbiology culture results 
 
Figure 4: PERiPLEX® results and peritonitis symptoms 
 
Figure 5: Picture of PERiPLEX® test 
 
Figure 6: Levels of IL-6 and MMP-8 in PD patients with acute peritonitis and control patients 
determined using PERiPLEX® and quantified using the Cube-Reader (opTricon, Germany). 
Each data point represents a patient; solid lines with error bars indicate geometric means and 
95% confidence intervals.  Dashed lines depict PERiLEX® cut-off values of 0.126 ng/ml for 
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